An indomitable particle: Colloidal silica takes on extreme environments

Scaling up production of an octapeptide therapeutic with solid phase synthesis

Brought to you by Bachem

Overview

Octreotide acetate is a therapeutic octapeptide analog of the naturally occurring hormone somatostatin. First approved for use in the United States in 1988, this synthetic peptide agonist is primarily used to treat adults with acromegaly. Most patients with acromegaly require life-long use of hormone therapy. New therapies such as oral formulations promise better disease control and quality of life for patients, but require 30-60 times higher octreotide ace¬tate concentrations, thus putting demand on complex active pharmaceutical ingredient manufacturers to cost-effectively scale production.

Learn how one pharmaceutical manufacturer used solid phase peptide synthesis to scale up octreotide acetate production 15-fold, producing validated product from the new process within 22 months.

Key Objectives:

How to make complex peptides at quality and scale
Upscaling octreotide acetate synthesis in a short timeline
Addressing regulatory services

Brought to you by:

This content was created by Bachem, without editorial input from the C&EN Media Group. For more information on C&EN's custom products, visit our C&EN Media Kit.

Please complete the form to download the white paper.

Forwarded this link? Clear the form

Email Address*

Salutation*

First Name*

Last Name*

Company*

Job Title

Address 1*

City*

State*

Zip / Post Code*

Country*

Business Phone*

I would like to receive more information on products and services from the American Chemical Society

address2

*By submitting this form, you agree to receive more information on related products and services from the American Chemical Society (ACS Publications) and its sponsor via email. ACS takes your privacy seriously. For more information, please see the ACS Privacy Policy.